Bristol-Myers Squibb
Why trials sponsored by Bristol-Myers Squibb stopped, in this sample of ClinicalTrials.gov.
27 stopped trials with a clear reason; 85% ended for non-scientific reasons.
| Reason | Trials | Share |
|---|---|---|
| funding business | 17 | 63% |
| slow accrual | 6 | 22% |
| futility | 2 | 7% |
| safety | 1 | 4% |
| other | 1 | 4% |
Where it ranks
- #2 of 90 sponsors by share of trials stopped for: funding or business decisions (63%).
Among ranked sponsors in this sample. Shares of stopped trials, not failure rates. See all scorecards.
Trials
- A Lactation Study in Women Receiving Treatment With Ozanimod
NCT06181630 · WITHDRAWN · other
“Replaced with another clinical trial” - A Study to Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic Syndromes or Beta-thalassemia
NCT07681440 · TERMINATED · slow accrual
“Insufficient enrollment” - A Study to Evaluate the Effect of Food on the Drug Levels of BMS-986196 in Healthy Adult Participants
NCT06034899 · WITHDRAWN · funding business
“Business objectives have changed.” - A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors
NCT05678283 · WITHDRAWN · funding business
“Business Objectives have changed.” - A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
NCT05168202 · TERMINATED · funding business
“Business objectives have changed” - A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis
NCT05064436 · TERMINATED · funding business
“Business objectives have changed” - A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
NCT03978611 · TERMINATED · funding business
“Business objectives have changed.” - A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy
NCT04151563 · WITHDRAWN · funding business
“Business objectives have changed” - Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)
NCT04267393 · TERMINATED · futility
“Trial terminated because of lack of efficacy in the short term acute phase.” - An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease
NCT03770299 · WITHDRAWN · funding business
“Business objectives have changed” - A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types
NCT04311710 · TERMINATED · funding business
“Business objectives have changed” - A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
NCT03519256 · TERMINATED · slow accrual
“Insufficient Enrollment” - An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed
NCT03444753 · TERMINATED · funding business
“business objectives have changed” - A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer
NCT03048136 · WITHDRAWN · funding business
“Business objective has changed” - An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread
NCT03446040 · TERMINATED · funding business
“Business objectives have changed” - First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors
NCT03110107 · TERMINATED · funding business
“Business Objectives have changed.” - Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents
NCT02928263 · WITHDRAWN · funding business
“Business objectives have changed” - Yervoy Pregnancy Surveillance Study
NCT02854488 · WITHDRAWN · slow accrual
“During the study period, no participants were enrolled in the study despite extensive recruitment methods.” - Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors
NCT01986218 · TERMINATED · funding business
“(Non-safety reason, business objectives have changed)” - Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV
NCT01866930 · TERMINATED · funding business
“Sponsor decision not based on any new unexpected safety findings or efficacy observations.” - Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
NCT01696045 · TERMINATED · slow accrual
“Slow accrual” - Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation
NCT01514864 · TERMINATED · slow accrual
“Lack of efficacy and slow accrual” - Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin
NCT01425970 · TERMINATED · safety
“Termination of study was due to safety reasons” - Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
NCT00430677 · TERMINATED · futility
“Terminated due to failure to meet the primary efficacy endpoint in the Short-term Period” - A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy
NCT00362466 · TERMINATED · slow accrual
“Insufficient Enrollment” - A Study of Abatacept in Patients With Active Crohn's Disease
NCT00406653 · TERMINATED · funding business
“Sponsor Decision” - MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma
NCT00298467 · WITHDRAWN · funding business
“sponsor decision”
Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.